2025 Germany Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 Germany Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in Germany include Alnylam Pharmaceuticals, CureVac AG, BioNTech, and Silence Therapeutics. Alnylam Pharmaceuticals is a global leader specializing in RNA interference technologies and has collaborations and presence influencing the German market. CureVac AG, headquartered in Tübingen, Germany, focuses on mRNA technologies, a platform closely related to RNA therapeutics, with strong expertise in mRNA vaccine and therapeutic development. BioNTech, located in Mainz and Idar-Oberstein, Germany, is renowned for its mRNA vaccines and biologics, also advancing RNA-based therapies. Silence Therapeutics, though UK-based, engages actively in the European antisense and RNAi market and has activities impacting Germany through regional collaborations and projects.
These companies contribute significantly to the growing German market, now generating over USD 159 million in 2024 and expected to grow at 21% CAGR to USD 493 million by 2030. Their efforts focus on various therapeutic areas including genetic disorders, cancer, and infectious diseases by developing innovative antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). Antisense RNA is currently the largest revenue segment, while RNA interference is fastest growing. Furthermore, Biotechnology firms such as siTOOLs Biotech and PRAMOMOLECULAR GmbH support the ecosystem with RNA molecule manufacturing and delivery research in Germany. This robust industrial and scientific presence positions Germany as a key player in Europe’s antisense and RNAi therapeutics markets.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in Germany include Alnylam Pharmaceuticals, CureVac AG, BioNTech, and Silence Therapeutics. Alnylam Pharmaceuticals is a global leader specializing in RNA interference technologies and has collaborations and presence influencing the German market. CureVac AG, headquartered in Tübingen, Germany, focuses on mRNA technologies, a platform closely related to RNA therapeutics, with strong expertise in mRNA vaccine and therapeutic development. BioNTech, located in Mainz and Idar-Oberstein, Germany, is renowned for its mRNA vaccines and biologics, also advancing RNA-based therapies. Silence Therapeutics, though UK-based, engages actively in the European antisense and RNAi market and has activities impacting Germany through regional collaborations and projects.
These companies contribute significantly to the growing German market, now generating over USD 159 million in 2024 and expected to grow at 21% CAGR to USD 493 million by 2030. Their efforts focus on various therapeutic areas including genetic disorders, cancer, and infectious diseases by developing innovative antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). Antisense RNA is currently the largest revenue segment, while RNA interference is fastest growing. Furthermore, Biotechnology firms such as siTOOLs Biotech and PRAMOMOLECULAR GmbH support the ecosystem with RNA molecule manufacturing and delivery research in Germany. This robust industrial and scientific presence positions Germany as a key player in Europe’s antisense and RNAi therapeutics markets.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
